Category: misconduct investigations

As third retraction for prominent physicist appears, university still won’t acknowledge investigation

Despite a university’s attempts to avoid discussing a misconduct investigation involving one of its former (and prominent) researchers, we keep reading more about it.

In the third retraction this year for physicist Dmitri Lapotko, the journal mentions a misconduct investigation at Rice University, which concluded the data had been falsified. Trouble is, whenever we’ve tried to talk to Rice about that investigation, they won’t even confirm it took place.

Here’s the retraction notice for “Transient Photothermal Spectra of Plasmonic Nanobubbles,” published by Langmuir:

Continue reading As third retraction for prominent physicist appears, university still won’t acknowledge investigation

Another retraction for student who confessed to cooking data

A journal has retracted another paper by a graduate student formerly based at Albert Einstein College of Medicine in New York, after she spontaneously confessed to fabricating data.

As we reported in April 2016, principal investigator Florence Marlow alerted the institution’s Office of Research Integrity and two journals about Meredyth Forbes’s admission, prompting an investigation into the extent of the data manipulation.

Three papers were affected: In January 2016, Development flagged one paper with an expression of concern, alerting readers to the potential issues with the data while the authors and Research Integrity Office investigated the scope of the problem. In April 2016, another paper was retracted by Cell Reports; the third, also published in Development, received a correction.

Last month, the authors and Development decided to retract the paper that had been flagged with an EOC (which appears on page 2 here).  Continue reading Another retraction for student who confessed to cooking data

Three figures in blood pressure paper were manipulated, says journal

A pharmacology journal has retracted a 2011 paper after concluding images in three figures had been manipulated.

According to the British Journal of Pharmacology, four of the five authors claim they played no role in the manipulation. There is no comment from the remaining author, first author Ian Morecroft, a research associate at the University of Glasgow.

Here’s more from the notice, which says an investigation at the University of Glasgow is ongoing:

Continue reading Three figures in blood pressure paper were manipulated, says journal

A diabetes researcher sued his former employer for defamation. Here’s the story.

Franck Mauvais-Jarvis

The last decade hasn’t exactly been drama-free for Franck Mauvais-Jarvis, head of the Diabetes Research Program at Tulane University.

After being accused of falsifying three figures in a submitted manuscript, Mauvais-Jarvis sued his accusers and officials at his former employer — Northwestern University — for defamation and conspiracy in 2011.

In 2014, a judge dismissed the suit. We wish we could tell you more details about it—such as what the university’s misconduct investigation found, or how the lawsuit was concluded—but they remain shrouded in mystery. What we know is based on court records from the lawsuit, which we recently obtained through an unrelated public records request. Even without all the details, it’s a long, sordid tale, involving a lot of finger-pointing and allegations of misconduct.

In 2008, a former research technician in the lab of Mauvais-Jarvis, then an associate professor of medicine at Northwestern University, raised concerns of fabrication in two figures in a paper on the regulation of insulin synthesis that had been submitted the Journal of Biological Chemistry. An inquiry committee at the university unanimously concluded that research misconduct charges against Mauvais-Jarvis were not credible.

But then a third figure in the manuscript was found to be “inaccurate,” and the university initiated a second inquiry. That’s when Mauvais-Jarvis — whose papers have been cited more than 2,000 times, according to Clarivate Analytics’ Web of Science, formerly part of Thomson Reuters — initiated a lawsuit. Continue reading A diabetes researcher sued his former employer for defamation. Here’s the story.

U.S. panel sounds alarm on “detrimental” research practices, calls for new body to help tackle misconduct

A new report from the U.S. National Academy of Sciences panel urges the creation of a new, independent group to help tackle research misconduct and other practices that hurt the enterprise.

The report also renames those problematic practices — such as “misleading statistical analysis that falls short of falsification,” awarding authorship to researchers who don’t deserve it (and vice versa), not sharing data, and poorly supervising research — as “detrimental” research practices. In the past, many have dubbed those behaviors as “questionable.”

The reason for the nomenclature change, according to a member of the Committee on Responsible Science (which wrote the report) CK Gunsalus, is to help the community understand that these aren’t just behaviors they should question — they can cause harm. Gunsalus, Director of the National Center for Professional and Research Ethics, told Retraction Watch:

Continue reading U.S. panel sounds alarm on “detrimental” research practices, calls for new body to help tackle misconduct

Cornell finds mistakes — not misconduct — in papers by high-profile nutrition researcher

Brian Wansink

An internal review by Cornell University has concluded that a high-profile researcher whose work has been under fire made numerous mistakes in his work, but did not commit misconduct.

In response, the researcher — Brian Wansink — announced that he has submitted four errata to the journals that published the work in question. Since the initial allegations about the four papers, other researchers have raised numerous questions about additional papers that appear to contain duplicated material. Wansink noted that he has contacted the six journals that published that work, and was told one paper is being retracted.

Here’s the statement from Cornell about its initial probe:

Continue reading Cornell finds mistakes — not misconduct — in papers by high-profile nutrition researcher

Star pediatric oncologist committed misconduct, ethical violations: reports

Stefaan Van Gool

A high-profile pediatric oncologist quietly left his former institution in 2015 after it concluded his clinical trials had been affected by significant “administrative problems.” But now the results of the university’s investigations and what followed have become public, after a paper in Belgium published a series of news reports last month.

We’re still hazy on some details of the case. The recent news reports allege that Van Gool started some clinical trials without proper ethical approvals and informed consent, and may have misled patients and their families about the benefits and potential side effects of his experimental treatment. Meanwhile, the CEO University Hospitals Leuven (UZLeuven) told us that Stefaan Van Gool, who had appointments at both the hospital and the university (KULeuven), left the hospital in 2015 as a result of administrative problems, but did not disclose the specific nature of these issues.

For the past 15 years or so, Van Gool has been developing and studying a vaccine to treat various cancers, initially at UZLeuven and, after September 2015, at a private clinic in Germany. Today, patients travel to his private clinic from all over the world and pay tens of thousands of dollars to receive the vaccine. But according to Flemish daily newspaper De Standaard, several years ago, UZLeuven began investigating his research and patient care practices. The outcome of these investigations was kept private until last month, after De Standaard published its reports.

Marc Decramer, the CEO of UZLeuven, confirmed that Van Gool left the hospital in 2015 and the university in 2016, but did not provide the specific reasons for his exit:

Continue reading Star pediatric oncologist committed misconduct, ethical violations: reports

Once-prominent researcher logs retraction following misconduct finding

A researcher who resigned from the University of Dundee in Scotland after it concluded he was guilty of misconduct has issued his first retraction.

According to an internal email to staff forwarded to us last year, the university concluded that Robert Ryan had misrepresented clinical data and images in 12 different publications. The first retraction, published by Molecular Microbiology, cites image duplications in multiple figures.

Here’s the full notice:

Continue reading Once-prominent researcher logs retraction following misconduct finding

Journals retract paper, flag two others by cancer doc under investigation

Carlo Croce

This weekend, Carlo Croce had some reprieve from the misconduct accusations that have followed him for years (recently described in a lengthy article in the New York Times) and that have prompted his university to re-open an investigation. On Sunday, he received a prestigious award from the American Association for Cancer Research, honoring his work.

But the moment may have been short-lived. Today, Croce received two expressions of concern (EOCs) from PNAS for two well-cited papers published over a decade ago, on which Croce — chair of the Department of Cancer Biology and Genetics at The Ohio State University (OSU) — is last author. The two EOCs cite concerns over duplicated bands. What’s more, another journal recently decided to retract one of his papers, citing figures that didn’t represent the results of the experiments.

PNAS chose to issue EOCs, rather than retractions or corrections, because the authors didn’t agree that the bands were duplicated, according to executive editor Diane Sullenberger. She explained how the journal learned of the issues with the two papers: Continue reading Journals retract paper, flag two others by cancer doc under investigation

German funder bans researcher for five years following misconduct probe

A researcher in Germany has been banned from seeking money from the largest independent research funder in the country for five years after an investigation by her former employer found her guilty of misconduct.

According to a recent announcement from the Deutsche Forschungsgemeinschaft (DFG), scientist Tina Wenz cannot apply for any DFG funding for five years, after a probe by the University of Cologne in Germany concluded she should retract six papers over misconduct.

A spokesperson for the DFG told us the agency funds more than 30,000 projects per year, and since 1998, has announced a ban due to data manipulation or misconduct only 10 times.

Continue reading German funder bans researcher for five years following misconduct probe